Anti-CCP assay will be run on the BioPlex 2200 system.

Bio-Rad gained access to Axis-Shield’s test for the early detection of rheumatoid arthritis. The assay will run on Bio-Rad’s BioPlex® 2200 system and will test for anticyclic citrullinated peptide antibodies.


“The ability to incorporate an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system,” points out John Goetz, Bio-Rad vp and group manager of clinical diagnostics. “As the first and only fully automated, random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multimarker autoimmune testing that includes rheumatoid arthritis.”

Previous articleBeckman Coulter Plans to Relocate Palo Alto Operations To Central Indiana
Next articleBMS Signs $100M Diabetes Deal with AstraZeneca